Currently, EZH2 is reported to be highly expressed in lymphomas, glioblastoma multiforme, ovarian, breast, and metastatic prostate cancers and is related to tumor progression, invasive growth, and poor prognosis in these tumors (Visser et al., 2001; Varambally et al., 2002; Bracken et al., 2003; Kleer et al., 2003; Yu et al., 2007; Hu et al., 2010; Orzan et al., 2011). The gene discussed is EZH2; the disease is glioblastoma.